Search

Your search keyword '"Caulkins, Jonathan P."' showing total 85 results

Search Constraints

Start Over You searched for: Author "Caulkins, Jonathan P." Remove constraint Author: "Caulkins, Jonathan P." Region united states Remove constraint Region: united states
85 results on '"Caulkins, Jonathan P."'

Search Results

1. Changes in self‐reported cannabis use in the United States from 1979 to 2022.

2. Rapid changes in illegally manufactured fentanyl products and prices in the United States.

3. CANNABIS LEGALIZATION AND SOCIAL EQUITY: SOME OPPORTUNITIES, PUZZLES, AND TRADE-OFFS.

4. When prohibition works: Comparing fireworks and cannabis regulations, markets, and harms.

5. Big data on a big new market: Insights from Washington State's legal cannabis market.

6. Lessons to be Drawn from U.S. Drug Control Policies.

7. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.

8. Recognizing and regulating cannabis as a temptation good.

9. Dealing More Effectively and Humanely with Illegal Drugs.

11. Advertising Restrictions on Cannabis Products for Nonmedical Use: Necessary but Not Sufficient?

12. CONTROLLING UNDERAGE ACCESS TO LEGAL CANNABIS.

13. Cocaine's fall and marijuana's rise: questions and insights based on new estimates of consumption and expenditures in US drug markets.

14. The Real Dangers of Marijuana.

15. Developing Public Health Regulations for Marijuana: Lessons From Alcohol and Tobacco.

16. High Tax States: Options for Gleaning Revenue from Legal Cannabis.

17. Scheduling of newly emerging drugs: a critical review of decisions over 40 years.

18. Marijuana Price Gradients: Implications for Exports and Export-Generated Tax Revenue for California After Legalization.

19. How Drug Enforcement Affects Drug Prices.

20. Modelling drug market supply disruptions: Where do all the drugs not go?

21. HIGH AND LOW FREQUENCY OSCILLATIONS IN DRUG EPIDEMICS.

22. Long-Run Trends in Incarceration of Drug Offenders in the United States.

23. Quality Cycles and the Strategic Manipulation of Value.

24. How many people does the U.S. imprison for drug use, and who are they?

25. CAPPS II: A Risky Choice Concerning an Untested Risk Detection Technology.

26. USING MODELS THAT INCORPORATE UNCERTAINTY.

27. How Large Should the Strike Zone Be in “Three Strikes and You're Out” Sentencing Laws?

28. OPTIMAL DYNAMIC ALLOCATION OF TREATMENT AND ENFORCEMENT IN ILLICIT DRUG CONTROL.

29. NOTICING THE MICRO-DISTRIBUTIONAL CONSEQUENCES OF CIGARETTE TAXATION AND ITS EQUIVALENTS.

30. Outcomes associated with scheduling or up-scheduling controlled substances.

31. Is crack cheaper than (powder) cocaine?

32. Setting goals for drug policy: harm reduction or use reduction?

33. The on-time machines: Some analyses of airline punctuality.

34. Heroin policy for the next decade.

35. Reorienting U.S. Drug Policy.

36. Does precursor regulation make a difference?

37. In praise of flawed treaties.

38. Response to Commentaries: new data sources for understanding cannabis markets.

39. Nonprofit Motive.

40. The US as an example of how not to legalize marijuana?

41. Beyond prevalence: importance of estimating drug consumption and expenditures.

42. Diminishing returns and great potential: a comment on Pollack's & Reuter's review on tougher drug enforcement and prices.

43. Price and purity analysis for illicit drug: Data and conceptual issues

44. RETHINKING THE WAR ON DRUGS.

45. Prescribing diamorphine in the United States: Insights from a nationally representative survey.

46. Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States.

47. Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids.

48. The Baltic and Nordic responses to the first Taliban poppy ban: Implications for Europe & synthetic opioids today.

49. Changing dynamics of drug overdoses in the United Kingdom: An attempt to replicate the Jalal et al. findings of steady exponential growth.

50. How much illegally manufactured fentanyl could the U.S. be consuming?

Catalog

Books, media, physical & digital resources